Skip to main content

Table 1 Patient characteristics according to the presence of any pulmonary function abnormalities

From: Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study

Characteristic No PFT abnormalities (n = 114) PFT abnormalities (n = 45) P value
Age (years) 61 ± 7.7 63 ± 9.9 0.14
Male gender 41 (36) 21 (47) 0.21
Caucasian 99 (87) 37 (82) 0.46
Body mass index (kg/m2) 29 ± 5.0 28 ± 5.5 0.12
Ever smoker 63 (55) 29 (64) 0.29
Current smoker 9 (7.9) 10 (22) 0.012
Reported lung disease 13 (11) 17 (38) < 0.001
   Emphysema 2 (1.8) 8 (18) < 0.001
   Asthma 12 (11) 8 (18) 0.22
   Rheumatoid lung disease 0 (0) 2 (4.7) 0.07
CAC > 100 34 (30) 19 (42) 0.14
RA characteristics    
   RA duration (years) 9.9 (5.6 to 18) 11 (7.1 to 23) 0.16
   RF seropositive 64 (56) 35 (78) 0.011
   Anti-CCP seropositive 67 (59) 37 (84) 0.003
   DAS28 (units) 3.1 (2.4 to 3.7) 3.1 (2.4 to 4.2) 0.74
   HAQ (units) 0.75 (0.13 to 1.5) 0.88 (0.13 to 1.5) 0.48
   Modified Sharp Score (units) 41 (12 to 99) 56 (25 to 140) 0.098
   Current prednisone 35 (31) 23 (51) 0.018
   Current nonbiologic DMARDs 99 (88) 38 (84) 0.60
   Current biologic DMARDs 55 (49) 20 (44) 0.63
Reported pulmonary symptoms    
   Any reported symptoms 41 (36) 26 (58) 0.012
   Any cough 19 (17) 16 (36) 0.010
   Any phlegm 22 (19) 16 (36) 0.030
   Any wheezing 17 (15) 18 (42) 0.001
   Any breathlessness 18 (16) 15 (33) 0.014
  1. Data expressed as mean ± standard deviation, n (%) or median (interquartile range). CAC, coronary artery calcium; CCP, cyclic citrullinated peptide; DAS28, RA Disease Activity Score in 28 joints; DMARDs, disease-modifying antirheumatic drugs; PFT, pulmonary function test; RA, rheumatoid arthritis; RF, rheumatoid factor.